E data: CD SGR JE JT ZAI SB JEB. Contributed reagents

E data: CD SGR JE JT ZAI SB JEB. Contributed reagents/materials/analysis tools: SGR MLKT SB JEB. Wrote the paper: CD SGR JE JT ZAI MLKT SB JEB.
Analysis ArticleDOI: 10.4274/Tjh.2012.Evaluation in the Security of Imatinib Mesylate in 200 Iraqi Sufferers with Chronic Myeloid Leukemia in the Chronic Phase: Single-Center Studymatinib Mesilatin Kronik Faz Kronik Myeloid L emi Tanili 200 Irakli Hastada G enirliinin Deerlendirilmesi: Tek Merkezli limaBassam Francis Matti1, Alaadin Sahham Naji1, Alaa Fadhil Alwan1Baghdad 2NationalTeaching Hospital, Clinical Hematology Department, Baghdad, Iraq Center of Hematology, Clinical Hematology Division, Baghdad, IraqAbstract: Objective: Imatinib mesylate, a tyrosine kinase inhibitor, is presently the drug of choice for chronic myeloid leukemia(CML). During therapy, a number of individuals may possibly create hematological and non-hematological adverse effects.Neuromedin B Purity & Documentation Components and Methods: The aim of this study was to evaluate the security of imatinib therapy in individuals with CML. Involving December 2007 and October 2009 two hundred sufferers with CML in chronic phase had been incorporated within the study. Written informed consent was obtained from all sufferers before the begin from the study. Imatinib was started at 400 mg orally every day. Patients have been monitored very carefully for any adverse effects. Complete blood count, liver, and renal function tests had been carried out once in two weeks throughout the initial month and on a month-to-month basis during follow-up. Toxicities that encountered had been graded as per the National Cancer Institute prevalent toxicity criteria version 2. Each hematologic and non-hematologic toxicities were managed with short interruptions of therapy and supportive measures, however the every day dose of imatinib was not lowered below 300 mg/day. Benefits: Two hundred CML patients in chronic phase were incorporated in this study; the male:female ratio was 0.7:1 with meanage 39.063.21 years (ranged from 15-81 years). The study showed that the commonest hematological side effects have been grade two anemia (12.five ) followed by leukopenia (8 ) and thrombocytopenia (four ), while one of the most widespread non-hematological adverse effects have been superficial edema and weight obtain (51.five ), followed by musculoskeletal discomfort (35.5 ), then gastro-intestinal symptoms (vomiting, diarrhea) (19 ). Fluid retention was the commonest side effect, which responded to low-dose diuretics. The drug was protected and effectively tolerated. There had been no deaths due to toxicity.Conclusion: Imatinib mesylate a well-tolerated drug, and all undesirable effects might be ameliorated easily. The mostcommon hematological and non-hematological unwanted side effects were anemia and fluid retention, respectively.IQ-3 Purity & Documentation Important Words: Safety, Imatinib, Chronic myeloid leukemiaAddress for Correspondence: Alaa Fadhil ALWAN , M.PMID:23775868 D., National Center of Hematology, Clinical Hematology Department, Baghdad, Iraq Phone: +9647702743114 E-mail: ala_sh73@yahoo Received/Geli tarihi : September 18, 2012 Accepted/Kabul tarihi : January 16,Turk J Hematol 2013;30:387-Matti1 BF, et al: Evaluation from the Safety of Imatinib Mesylate in 200 Iraqi Sufferers with Chronic Myeloid Leukemia inside the Chronic Phase: Single-Center Studyet: Ama Bir tirozin kinaz inhibit olan imatinib mesilat, g kronik miyeloid l emi (KML) itedavisinde ilk se nekila ir. Tedavi sirasinda az sayida hastada hematolojik ve non-hematolojik yan etkiler geliebilir.Gereve Y temler: Bu limanin amaci KML hastalarinda imatinib tedavisinin g enirliini deerlendirmektir. Aralik2007-Ekim 2009 arasinda kronik faz.